Printer Friendly

SCHERER ANNOUNCES CREATION OF NEW DEVELOPMENT GROUP

 TROY, Mich., Sept. 27 /PRNewswire/ -- R.P. Scherer Corporation (NYSE: SHR) announced today the formation of a new internal group to manage the development and registration of pharmaceutical products incorporating off-patent compounds and Scherer's proprietary drug delivery technologies. The name of the new group will be "Advanced Therapeutic Products" and it will be based in the U.K., within the management of R.P. Scherer's new drug delivery division, Scherer D.D.S. Key management personnel will be Peter Virley, Managing Director, Dr. Stewart Johnson, Medical Director, Dr. Harry Seager, Technical Director, and Lionel Tebbutt, Finance Director. A team of clinical, regulatory and data management experts will be located in Swindon, England.
 Making the announcement at Scherer's Annual Shareholders' Meeting held today in New York, Alex Erdeljan, President of R.P. Scherer Corporation, stated: "It is our intention to capitalize on current industry and market trends and develop new products with demonstrably improved therapeutic and cost benefits over existing treatments. We believe that each of our proprietary drug delivery systems can add significant therapeutic value in many clinical situations. For the first time, Scherer, rather than its customers, will be directly responsible for the planning and execution of the clinical development of products utilizing our own unique technologies. In time, we expect this effort to result in products and therapies which will successfully address growing demands for cost effective pharmaceuticals, as well as in creation of additional value for our shareholders."
 In commenting further on the activities of the new development group, Scherer president said that, "while this effort represents an important step in the evolution of Scherer from a technology development company, to a product development company, it is complementary to our existing primary activity of customer-led contract development and manufacturing operations. It is our expectation that the activities of this group will speed up and enlarge the scope of commercialization of our proprietary Scherersol, Zydis and Pulsincap drug delivery systems."
 The management of the Advanced Therapeutic Products (ATP) group has already selected seven products for priority development, and anticipates that the first clinical studies will start early in 1994.
 R.P. Scherer Corporation, an international developer and manufacturer of drug delivery systems, is the world's largest producer of soft gelatin capsules ("softgels"). The company is currently developing and commercializing advanced drug delivery systems, including SCHERERSOL(TM), ZYDIS(R) and PULSINCAP(TM) technologies. The company's proprietary drug delivery systems improve the efficacy of drugs by regulating the dosage, rate of absorption and place of release. The company operates a global network of 18 facilities in 11 countries.
 -0- 9/27/93
 /CONTACT: Nicole Williams, Executive VP & CFO of R.P. Scherer, 313-649-0900/
 (SHR) CO: R.P. Scherer Corporation ST: Michigan IN: MTC SU:


ML -- DE015 -- 5925 09/27/93 12:29 EDT
COPYRIGHT 1993 PR Newswire Association LLC
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 1993 Gale, Cengage Learning. All rights reserved.

Article Details
Printer friendly Cite/link Email Feedback
Publication:PR Newswire
Date:Sep 27, 1993
Words:463
Previous Article:NEW TOLL FRAUD TREND: MORE SMALL COMPANIES ARE TARGETED BY HACKERS
Next Article:HOME SHOPPING NETWORK'S EXPANDING OUTLET STORE DIVISION CELEBRATES NEWEST STORE
Topics:

Terms of use | Copyright © 2017 Farlex, Inc. | Feedback | For webmasters